Saxenda (Liraglutide) Lawsuit

Saxenda lawsuits are being filed against drugmaker Novo Nordisk, claiming that the GLP-1 (glucagon-like peptide-1) drug caused sudden and irreversible vision loss known as non-arteritic anterior ischemic optic neuropathy (NAION).

Lawsuits also allege that the manufacturer didn’t adequately warn patients about this risk.

Similar lawsuits have been filed against GLP-1 drugs Ozempic and Wegovy. These cases are ongoing and may be consolidated into multicounty litigation (MCL). An MCL consists of lawsuits with similar defendants and facts that are grouped together.

Saxenda users might be able to join the MCL.

Saxenda Lawsuits for Gastrointestinal Problems

In addition to NAION lawsuits, people have filed Saxenda lawsuits because of gastrointestinal problems like paralyzed stomach (gastroparesis) and bowel obstruction.

The gastroparesis litigation also includes Ozempic and Mounjaro lawsuits.

Other GLP-1 Vision-Loss Lawsuits

There are 21 lawsuits in New Jersey alleging Novo Nordisk didn’t warn that their GLP-1 diabetes and weight loss drugs Ozempic and Wegovy can trigger NAION.

In June 2025, plaintiffs’ attorneys asked New Jersey’s Supreme Court to consolidate NAION cases in an MCL. Comments or objections to the MCL are due by August 29, 2025.

This litigation has just started. There have been no trials or settlements.

You might be eligible to file a Saxenda NAION lawsuit if you took the drug and were diagnosed with NAION afterward.

If you aren’t sure whether you qualify to file a Saxenda lawsuit, contact a lawyer. They can tell you if you qualify.

When you talk to an attorney, make sure to gather your medical records, receipts, vision test results and other evidence that shows you took Saxenda and later developed vision loss.

Some lawyers estimate the average settlement payout for eye injuries like those associated with Saxenda, including vision loss or total blindness, could be $500,000 or more.

Since there haven’t been any settlements or jury verdicts for Saxenda eye injuries, the exact settlement payout can’t be determined yet. No exact amount is guaranteed.

Factors that affect Saxenda settlement amounts include how serious your injury is and what other physical, mental or emotional losses you experienced because of your use of the drug.

The easiest way to file a Saxenda NAION lawsuit is to sign up for a free case review through Drugwatch. You can learn about your legal rights and whether you have a case, with no pressure to file a lawsuit.

Plus, you don’t pay anything to your lawyer unless they win your case. There’s no risk involved.

When you hire your lawyer, they can answer your questions about what to expect. They will also coach you every step of the way.

Saxenda is a prescription medication that’s approved by the U.S. Food & Drug Administration (FDA) to help people with obesity or who are overweight lose weight. It’s also approved for children aged 12 and up who meet specific criteria.

The active ingredient is liraglutide, which mimics the action of a natural hormone in the body called GLP-1. This hormone helps control blood sugar in patients with Type 2 diabetes. Saxenda contains the same active ingredient as Victoza, an FDA-approved drug that treats Type 2 diabetes.

People who take Saxenda lose weight because the drug decreases hunger, increases feelings of fullness and slows the movement of food out of their stomach. Studies show that users typically lose 3% to 8% of their initial body weight. Some people may lose more.

Ozempic and Wegovy are similar medications, but they contain another GLP-1 drug called semaglutide. Ozempic is FDA-approved to treat Type 2 diabetes, while Wegovy is approved for weight loss.

Saxenda side effects include mild, common side effects like constipation, diarrhea and nausea. Serious side effects include kidney problems from dehydration, severe stomach issues and thyroid tumors.

The FDA added a black box warning to Saxenda due to a potentially increased risk of thyroid C-cell tumors. The warning states that researchers found these tumors in animal studies for liraglutide, but they don’t know if these tumors can form in humans.

Studies have linked Saxenda to NAION. A 2024 study in Epic Research found patients who took liraglutide had a 179% greater likelihood of being diagnosed with NAION than those prescribed other diabetes medications.

A 2025 research letter published in JAMA Ophthalmology found liraglutide increased the risk of NAION by 25%. It also found that semaglutide increased the risk of NAION by 39%.